Stock·NYSE·Technology
Celestica Inc. (CLS)
- Market cap
- $33.49B
- P/E
- 25.05
- Dividend yield
- None
- Street target
- $480.00median of 22 analysts
- 52-week range
- $244.51 $474.03
CLS stock forecast today
Where CLS stands today, and what CleaRank Financial AI makes of it.
CLS at a glance
Celestica Inc. (CLS): Buy, 63/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($324.55 and $332.27).
- Earnings CLS beat estimates in 8 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $253.8M and bought $2.1M over the last 18 months.
- Valuation P/E of 25.1 against 35.1 for the Technology sector: a discount to peers (-29%).
Figures as of October 30, 2026.
CleaRank Financial AI
CleaRank rates Celestica Inc. (CLS) Buy, with a model score of 63/100.
The analysts' outlook lifts the score most: 22 of 22 analysts rate it a buy and the median target is 80.8% above the price. The trend holds it back most: the price is 20.09% below its 200-day average and 18.19% below its 50-day average, and the 50-day average is 2.32% below the 200-day. The 50-day average stands at $324.55 and the 200-day at $332.27. Over the past year the price fell 21.93%.
Only on CleaRank
Figures we compute ourselves from CLS's own price, earnings and insider-filing history. Tap one to see it in context.
CLS stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price below its 50-day average ›
The price of $265.53 is 18.2% below the 50-day simple moving average of $324.55.Price below its 200-day average ›
The price is 20.1% below the 200-day simple moving average of $332.27.50-day average below the 200-day ›
The 50-day average ($324.55) is 2.3% below the 200-day average ($332.27), the arrangement of a falling longer-term trend.In the lower half of its 52-week range ›
The price sits at 9% of its 52-week range, between $244.51 and $474.03.
CLS share price
Pick a period: each tab shows how far CLS has moved over it, to the last close.
Today's trading
Where CLS sits inside today's range and its 52-week range.
CLS fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 25.05 is 28.6% below the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 1.84 is 75.8% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $1.2B on revenue of $18.2B, a net margin of 6.8%.Beat estimates in most recent reports ›
CLS beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for CLS.
As of October 30, 2026, CLS trades at $265.53, with a market value of $33.49B and a P/E ratio of 25.05.
What the numbers say
CleaRank Financial AI's reading of CLS's valuation, growth and risks.
CLS trades at a discount to peers on earnings. Its P/E of 25.05 is 28.6% below the 35.1 median P/E of Technology stocks. On sales, the P/S of 1.84 is 75.8% below the sector median of 7.6. Market capitalisation stands at $33.5B, and trailing earnings are $10.60 a share.
Turning sales into profit, the company posts a net margin of 6.83% and an operating margin of 7.91%. Return on equity stands at 30.23%, above the sector median of 13.4%. Debt-to-equity of 0.17 indicates a lightly indebted balance sheet.
Celestica Inc. (CLS) beat expectations in its October 26, 2026 report, posting EPS of $3.30 against an estimate of $2.96, a beat of 11.49%. The stock climbed 12.12% in the following session.
The record is a clean sweep: 8 beats in 8 reports; even so, 3 of those 8 beats were followed by a lower share price the next session. Analysts' average EPS estimate for this fiscal year is $11.17, which would be growth of 84.6%, and $19.45 for next year (growth of 74.2%).
CLS is a volatile stock, moving 4.89% on an average session, and its beta against the S&P 500 is 1.32. Until the price gets back above its moving averages, the trend is a headwind for anyone holding the shares. The stock is 43.98% below its 52-week high of $474.03. Over the last 18 months insiders sold $253.8M of stock and bought $2.1M. Insider sales are often planned in advance, so they carry less weight than purchases would.
CLS against the Technology sector
How CLS compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: CLS trades at a notable discount to sector peers (-29%), which may indicate undervaluation or specific company headwinds.
Return vs XLK: Since May 20, 2025, CLS has gained 135.7% against a gain of 53.7% for XLK.
Performance against XLK
CLS and the Technology sector fund over the same days.
Revenue and earnings
How much CLS sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); CLS reported again on October 26, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 28.5% in FY2025 to $12.4B, from $9.6B a year earlier.
Profit margin: The net margin was 6.7% in FY2025, up from 4.4% the year before.
Profitable: CLS earned $833M in FY2025.
Earnings reality check
Did CLS beat what analysts expected, and how did the stock react?
Earnings record: CLS beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 26, 2026after close | $2.96 | $3.30 | +11.49% | +12.12% | - |
| Jul 27, 2026after close | $2.31 | $2.54 | +9.96% | +10.04% | +7.44% |
| Apr 27, 2026after close | $2.07 | $2.16 | +4.35% | -14.37% | -0.35% |
| Jan 28, 2026after close | $1.76 | $1.89 | +7.39% | -13.10% | -20.09% |
| Oct 27, 2025after close | $1.49 | $1.58 | +6.04% | +8.16% | +15.64% |
| Jul 28, 2025after close | $1.23 | $1.39 | +13.01% | +16.51% | +16.20% |
| Apr 24, 2025after close | $1.12 | $1.20 | +7.14% | -3.35% | -3.18% |
| Jan 29, 2025after close | $1.06 | $1.11 | +4.72% | +13.59% | +42.97% |
As of October 30, 2026, CLS has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on October 26, 2026, came in 11.49% above the estimate and the stock moved +12.12% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CLS AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 37.9, showing bearish momentum without being oversold.RSI below 50 ›
An RSI of 37.9 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line below zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of CLS
The score, the reasoning behind it, and what could move the price next.
Celestica Inc. (CLS) is in a downtrend. At $265.53 the stock sits 20.09% below its 200-day average of $332.27 and 18.19% below its 50-day average of $324.55. It is also near the floor of its 52-week range: 8.60% above the low of $244.51, while 43.98% below the high of $474.03. Both averages point the same way, with the 50-day 2.32% below the 200-day.
The 14-day RSI of 37.9 is in the bearish zone, above the oversold line, and the MACD line is negative. The price is down over each of these periods: 26.53% over the past month, 19.89% over the past three months and 21.93% over the past year. Volume in the last session ran 26.5% below its average, on a day the price fell 6.09%.
Earnings beat ›
The October 26, 2026 report beat the EPS estimate by 11.49%, and the share price rose 12.12% in the first session after it.
Source: Earnings report, October 26, 2026New analyst coverage ›
Bernstein started coverage at Outperform on September 30, 2026.
Source: Analyst action, Bernstein, September 30, 2026New analyst coverage ›
FBN Securities started coverage at Outperform on September 15, 2026.
Source: Analyst action, FBN Securities, September 15, 2026
- Two levels are closest to the price: the 20-day EMA at $303.30 sits above it, and the 52-week low at $244.51 sits below it.
- The 14-day RSI reads 37.9, in the bearish zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- CLS rose 12.12% in the first session after its October 26, 2026 report. Across the last 8 reports, the company has beaten estimates in every one.
CLS sits below its 50-day and 200-day moving averages ($324.55 and $332.27), and that placement is why the trend reads as down. A recovery would first show up as a move back above the 50-day. The first level overhead is the 20-day EMA at $303.30.
For CLS, the next level below the price is the 52-week low at $244.51. With the RSI in the bearish zone, momentum still leans lower.
Technical indicators
Momentum and trend for CLS, from its daily closes.
As of October 30, 2026, with CLS at $265.53, its 14-day RSI is 37.9 (showing bearish momentum without being oversold), its 50-day simple moving average is $324.55 and its 200-day is $332.27.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CLS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, CLS's 1-year correlation of daily returns is +0.53 with S&P 500 (SPY), +0.61 with Nasdaq 100 (QQQ), +0.25 with Bitcoin (BTC) and +0.19 with gold (XAU).
CLS price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
22 of 22 analysts rate it a buy or strong buy, 0 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $480.00 is 80.8% above the price.More buy ratings than three months ago ›
22 of 22 rate it a buy now, against 19 of 20 three months ago.
CLS Wall Street View
12-month price targets
The price, $265.53, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 30, 2026 | Bernstein | Initiates | Outperform |
| Sep 15, 2026 | FBN Securities | Initiates | Outperform |
| Aug 24, 2026 | UBS | Upgrade | Buy |
| Aug 11, 2026 | Scotiabank | Reinstates | Sector Outperform |
| Aug 7, 2026 | Barclays | Maintains | Overweight |
| Jul 29, 2026 | JP Morgan | Maintains | Overweight |
As of October 30, 2026, 22 Wall Street analysts cover CLS: 22 rate it a buy or strong buy, 0 a hold and 0 a sell or strong sell. Their 12-month price targets range from $375.00 to $550.00. The median CLS price target is $480.00, 80.8% above the price of $265.53.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CLS trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CLS trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
CLS moves about 4.9% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CLS tends to move, against the market and on its own.
CLS price history and drawdowns
CLS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move of 2% or more ›
The price has moved 4.89% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 79.8%, from April 2017 to March 2020, regained by June 2023.Most 1-year holds ended higher ›
66% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $224,076, against $41,607 in the S&P 500 (SPY).
CLS Drawdowns & Recovery
As of October 30, 2026, CLS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -79.8% (April 2017 to March 2020); it regained that peak by June 2023, 39 months after the low, and 66% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CLS in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CLS beat the S&P 500 over this period: $224,076 against $41,607.
A $10,000 investment in CLS in October 2016 would be worth about $224,076 today with dividends reinvested, compared with about $41,607 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CLS, and which have not.
Strongest month, May: an average of +10.49%, up in 6 of 10 years.
Weakest month, March: an average of -5.92%, up in 4 of 10 years.
This month, October: has averaged +7.92%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CLS's strongest calendar month has been May (average +10.49%, up in 6 of 10 years) and its weakest March (average -5.92%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
CLS stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CLS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in CLS today could grow to about $15,535 by 2030 in the base case, with a 90th-percentile outcome near $55,963 and a 10th-percentile outcome around $4,312. Projections are statistical simulations, not guarantees.
CLS Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $413 for CLS by 2030 in the base case, from $266 today (1.6x over 4 years). The 10th-percentile path ends near $115. These are outcomes of a Monte Carlo simulation run on CLS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $156 | $296 | $563 | |
| 2028 | $134 | $331 | $819 | |
| 2029 | $122 | $369 | $1,121 | |
| 2030 | $115 | $413 | $1,486 |
Method: a lognormal simulation of CLS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. CLS is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. How the simulation works
CLS insider trading
What the people running the company have bought and sold.
CLS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $2.1M on the open market and sold $253.8M.
As of October 30, 2026, CLS insiders reported 22 open-market sales worth $253.8M and 1 open-market purchase worth $2.1M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Robert A Cascella
Director
|
Grant | 52 | - |
| Sep 30, 2026 | Jill Kale
Director
|
Grant | 96 | - |
| Sep 23, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 23.4K | $8.5M |
| Sep 23, 2026 | Todd Christopher Cooper
President
|
Sell | 20.1K | $7.2M |
| Aug 13, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 23.5K | $8.5M |
| Aug 5, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 51.1K | $18.8M |
| Aug 4, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 98.5K | $36.3M |
| Aug 4, 2026 | Mandeep Chawla
Chief Financial Officer
|
Sell | 16.1K | $6.0M |
| Jul 31, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 9.5K | $3.5M |
| Jul 31, 2026 | Mandeep Chawla
Chief Financial Officer
|
Sell | 883 | $323.6K |
| Jun 30, 2026 | Robert A Cascella
Director
|
Grant | 84 | - |
| Jun 30, 2026 | Jill Kale
Director
|
Grant | 155 | - |
| Jun 17, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 18.2K | $7.0M |
| Jun 16, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 55.8K | $21.6M |
| Jun 15, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Sell | 66.1K | $26.4M |
| Jun 15, 2026 | Mandeep Chawla
Chief Financial Officer
|
Sell | 17.0K | $6.8M |
| May 19, 2026 | Michael Max Wilson
Director
|
Sell | 4.2K | $1.4M |
| May 19, 2026 | Michael Max Wilson
Director
|
Grant | 8.7K | - |
| Mar 31, 2026 | Robert A Cascella
Director
|
Grant | 156 | - |
| Mar 31, 2026 | Jill Kale
Director
|
Grant | 287 | - |
| Mar 31, 2026 | Michael Max Wilson
Director
|
Grant | 3.2K | - |
| Feb 6, 2026 | Jason Phillips
President
|
Sell | 120.0K | $36.9M |
| Feb 6, 2026 | Todd Christopher Cooper
President
|
Grant | 15.6K | - |
| Feb 5, 2026 | Theodoros Tzevelekis
Officer
|
Grant | 4.2K | - |
| Feb 4, 2026 | Yann Louis Etienvre
Chief Operating Officer
|
Sell | 1.1K | $324.6K |
| Feb 4, 2026 | Todd Christopher Cooper
President
|
Sell | 1.1K | $301.9K |
| Feb 4, 2026 | Todd Christopher Cooper
President
|
Grant | 2.0K | - |
| Feb 4, 2026 | Yann Louis Etienvre
Chief Operating Officer
|
Grant | 2.2K | - |
| Feb 4, 2026 | Jason Phillips
President
|
Grant | 2.5K | - |
| Feb 2, 2026 | Todd Christopher Cooper
President
|
Sell | 89.5K | $25.7M |
| Feb 2, 2026 | Yann Louis Etienvre
Chief Operating Officer
|
Sell | 86.2K | $24.8M |
| Feb 2, 2026 | Leila Wong
Officer
|
Sell | 30.0K | $8.6M |
| Feb 2, 2026 | Douglas Michael Parker
Officer
|
Sell | 2.7K | $781.7K |
| Feb 2, 2026 | Mandeep Chawla
Chief Financial Officer
|
Grant | 191.1K | - |
| Feb 2, 2026 | Todd Christopher Cooper
President
|
Grant | 166.8K | - |
| Feb 2, 2026 | Yann Louis Etienvre
Chief Operating Officer
|
Grant | 167.0K | - |
| Feb 2, 2026 | Robert Andrew Mionis
Chief Executive Officer
|
Grant | 814.1K | - |
| Feb 2, 2026 | Douglas Michael Parker
Officer
|
Grant | 5.9K | - |
| Feb 2, 2026 | Jason Phillips
President
|
Grant | 181.6K | - |
| Feb 2, 2026 | Leila Wong
Officer
|
Grant | 64.5K | - |
| Dec 31, 2025 | Michael Max Wilson
Director
|
Grant | 4.3K | - |
| Dec 1, 2025 | Yann Louis Etienvre
Chief Operating Officer
|
Sell | 9.2K | $3.0M |
| Dec 1, 2025 | Leila Wong
Officer
|
Sell | 3.2K | $1.0M |
| Dec 1, 2025 | Mandeep Chawla
Chief Financial Officer
|
Grant | 20.4K | - |
| Dec 1, 2025 | Todd Christopher Cooper
President
|
Grant | 17.8K | - |
| Dec 1, 2025 | Yann Louis Etienvre
Chief Operating Officer
|
Grant | 17.8K | - |
| Dec 1, 2025 | Robert Andrew Mionis
Chief Executive Officer
|
Grant | 86.7K | - |
| Dec 1, 2025 | Jason Phillips
President
|
Grant | 19.4K | - |
| Dec 1, 2025 | Leila Wong
Officer
|
Grant | 6.8K | - |
| Oct 30, 2025 | Laurette T Koellner
Director
|
Buy | 6.0K | $2.1M |
| Sep 30, 2025 | Michael Max Wilson
Director
|
Grant | 5.7K | - |
| Aug 1, 2025 | Todd Christopher Cooper
President
|
Grant | 11.0K | - |
| Jun 30, 2025 | Michael Max Wilson
Director
|
Grant | 5.9K | - |
Source: TwelveData, from reported insider filings
CLS stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.